SER

Serina Therapeutics Inc. (SER) | Rumor.io

Serina Therapeutics

SER

Attention (50-day avg)0%

Attention rank (50-day avg)#3,560

Bullish sentiment (50-day avg)100%

Price to earnings ratio1.58

Market capitalization51.1M

Earnings per share-1.87

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-19.2M

Social

What share of all stock conversation is about SER?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

May 21

$SER has a market capitalization of 500k, making it easy to double bag.
The token satirizes the hustle culture of low-follower accounts desperately grinding for attention on crypto Twitter, particularly the reply guys who spam every thread begging for airdrops.
$SER is the first coin launched on the Solana network and has great potential in the future, with some users reporting 22.3x profit from their call on the token.

Generated by AI

Sentiment

Of the messages about SER that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	88.9% +6.28
Bearish	—	—	—	11.1% -6.28

Bullish· May 21

$SER has shown a significant 10.4X return on investment, making it a standout performer in the market.
The asset is still in an "up only season," with the community pushing for it to reach new heights and break through to even greater gains.
The chart for $SER is reclaiming its all-time high, and volume is decent, indicating a strong bullish sentiment among investors.

Bearish· Mar 19

$SER's price has experienced significant drops, releasing liquidity and potentially leading to further declines.
The asset's price has broken below 2.10, indicating a loss of momentum and increasing the likelihood of a sharp decline.
Short sellers are facing significant losses, with some having covered their positions or being on the verge of margin calls, suggesting a bearish sentiment among market participants.

Generated by AI

Topics

Of the messages about SER that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	14%
Announcements	—	—	—	1.25%
Controversies	—	—	—	0%
Earnings	—	—	—	0.01%
Macro	—	—	—	83.44%
Technical Analysis	—	—	—	1.3%

Announcements· Feb 3

Institutions have been building ownership in Serina Therapeutics (SER) over multiple quarters, signaling durability.
Serina Therapeutics (SER) has seen a significant increase in throughput, reaching 2.53M gallons per month, indicating scale building.
Institutional math matters more than headlines for Serina Therapeutics (SER), with volume expansion of +308% YoY confirming demand strength.

Technical Analysis· Mar 20

The author is looking for a S/D flip over daily highs for SER to reach the next leg higher, with a potential range to $3.3/$3.6+.
A reversal is expected in SER, with a trend reversal possible between 1-2pm.
SER has shown up on scanners lately, indicating traders are watching for a continuation setup, with a potential break through the 2.75 resistance.

Generated by AI

Community

Of the messages about SER, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	10%	2.01%
Newcomers	—	—	90%	97.99%

May 11

New users are discussing the potential of Serina Therapeutics, Inc. in the biotech sector.
Some newcomers are comparing Serina Therapeutics, Inc. to other companies in the same sector, highlighting their unique features.
There is interest among newcomers in the clinical trials and research being conducted by Serina Therapeutics, Inc.

Generated by AI

HUNTSVILLE, AL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology enabling drug product candidates to treat neurological diseases and other indications, today announced that Steve Ledger, Chief Executive Officer, will present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference. The Company will also attend o

19d agoYahoo Finance

Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2

- Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data – - Pharmacokinetic observations at the lowest dose evaluated were consistent with the sustained apomorphine exposure SER-252 is designed to provide – - Blinded Cohort 1 observations included sustained periods of improvement in motor function in individual patients on exploratory clinical measures – - Serina expects to report topline data from the single-

21d agoYahoo Finance

Serina Therapeutics Establishes Flexible Equity Financing Agreement

Detailed price information for Serina Therapeutics Inc (SER-A) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Analysts Are Bullish on These Healthcare Stocks: Tvardi Therapeutics (TVRD), GE Healthcare Technologies Inc (GEHC)

Detailed price information for GE Healthcare Technologies (GEHC-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Enrollment and dosing completed in Cohort 1 of Phase 1b registrational study of SER-252 -Top-line data from the single-ascending-dose arm targeted for the first half of 2027 - Appointment of Farrell Simon, Pharm.D., to the Board of Directors - HUNTSVILLE, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its finan

1mo agoYahoo Finance

Also Discussed

Investors talking about SER also mention

#	Name	Attention
1	Tharimmune Inc.THAR	0%new
2	Zhongchao Inc. Class A Ordinary SharesZCMD	0%new
3	Skillsoft Corp. Class A Common StockSKIL	0%0
4	SPDR MSCI ACWI ex-US ETFCWI	0%new
5	Captivision Inc.CAPT	0%new
6	Deluxe CorpDLX	0%new
7	Rein Therapeutics Inc.RNTX	0%0
8	Agape Atp CorpATPC	0%0
9	Designer Brands IncDBI	0%new
10	Nuveen New York Quality Municipal Income FundNAN	0%new

Serina Therapeutics Inc.

Healthcare
Biotechnology

Serina Therapeutics Inc., a biopharmaceutical company, focuses on the development of polymer-based therapeutics to address significant medical challenges. The company's primary innovation lies in its proprietary polyoxazoline (POZ) polymer technology, which is engineered to enhance the delivery and efficacy of pharmaceuticals. This novel platform aims to improve the pharmacokinetics and safety profiles of their drug candidates, making it a promising solution for patients with unmet medical needs. Serina Therapeutics operates within the biotechnology and pharmaceutical sectors, emphasizing the treatment of neurological diseases, cancer, and autoimmune conditions. The company's POZ technology has the potential to impact the drug delivery landscape, offering tailored solutions that prolong the drug's duration in the system and minimize side effects, thereby increasing therapeutic efficacy. In the competitive landscape of biopharmaceutical innovation, Serina Therapeutics Inc. plays a vital role by advancing the development of next-generation therapeutics that align with the evolving demands of precision medicine.

Website

Location

601 Genome Way

Huntsville, AL, 35806

United States

Social

What share of all stock conversation is about SER?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

May 21

$SER has a market capitalization of 500k, making it easy to double bag.
The token satirizes the hustle culture of low-follower accounts desperately grinding for attention on crypto Twitter, particularly the reply guys who spam every thread begging for airdrops.
$SER is the first coin launched on the Solana network and has great potential in the future, with some users reporting 22.3x profit from their call on the token.

Generated by AI

Sentiment

Of the messages about SER that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	88.9% +6.28
Bearish	—	—	—	11.1% -6.28

Bullish· May 21

$SER has shown a significant 10.4X return on investment, making it a standout performer in the market.
The asset is still in an "up only season," with the community pushing for it to reach new heights and break through to even greater gains.
The chart for $SER is reclaiming its all-time high, and volume is decent, indicating a strong bullish sentiment among investors.

Bearish· Mar 19

$SER's price has experienced significant drops, releasing liquidity and potentially leading to further declines.
The asset's price has broken below 2.10, indicating a loss of momentum and increasing the likelihood of a sharp decline.
Short sellers are facing significant losses, with some having covered their positions or being on the verge of margin calls, suggesting a bearish sentiment among market participants.

Generated by AI

Topics

Of the messages about SER that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	14%
Announcements	—	—	—	1.25%
Controversies	—	—	—	0%
Earnings	—	—	—	0.01%
Macro	—	—	—	83.44%
Technical Analysis	—	—	—	1.3%

Announcements· Feb 3

Institutions have been building ownership in Serina Therapeutics (SER) over multiple quarters, signaling durability.
Serina Therapeutics (SER) has seen a significant increase in throughput, reaching 2.53M gallons per month, indicating scale building.
Institutional math matters more than headlines for Serina Therapeutics (SER), with volume expansion of +308% YoY confirming demand strength.

Technical Analysis· Mar 20

The author is looking for a S/D flip over daily highs for SER to reach the next leg higher, with a potential range to $3.3/$3.6+.
A reversal is expected in SER, with a trend reversal possible between 1-2pm.
SER has shown up on scanners lately, indicating traders are watching for a continuation setup, with a potential break through the 2.75 resistance.

Generated by AI

Community

Of the messages about SER, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	10%	2.01%
Newcomers	—	—	90%	97.99%

May 11

New users are discussing the potential of Serina Therapeutics, Inc. in the biotech sector.
Some newcomers are comparing Serina Therapeutics, Inc. to other companies in the same sector, highlighting their unique features.
There is interest among newcomers in the clinical trials and research being conducted by Serina Therapeutics, Inc.

Generated by AI

Serina Therapeutics

Social

May 21

Sentiment

Bullish· May 21

Bearish· Mar 19

Topics

Announcements· Feb 3

Technical Analysis· Mar 20

Community

May 11

News

Serina Therapeutics at H.C. Wainwright conference: Parkinson’s push advances

Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2

Serina Therapeutics Establishes Flexible Equity Financing Agreement

Analysts Are Bullish on These Healthcare Stocks: Tvardi Therapeutics (TVRD), GE Healthcare Technologies Inc (GEHC)

Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Also Discussed

Serina Therapeutics Inc.

Company Information

Location

Social

May 21

Sentiment

Bullish· May 21

Bearish· Mar 19

Topics

Announcements· Feb 3

Technical Analysis· Mar 20

Community

May 11

News

Serina Therapeutics at H.C. Wainwright conference: Parkinson’s push advances

Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2

Serina Therapeutics Establishes Flexible Equity Financing Agreement

Analysts Are Bullish on These Healthcare Stocks: Tvardi Therapeutics (TVRD), GE Healthcare Technologies Inc (GEHC)

Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Also Discussed